NCT05823896 - ImPROving Quality of LIFe in the Long COVID Patient | Biotech Hunter

Enrollment

219

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

November 28, 2024

Study Completion Date

November 28, 2024

Conditions

Post-COVID-19 SyndromeLong COVIDLong Covid19COVID-19POTS - Postural Orthostatic Tachycardia SyndromePost COVID-19 ConditionPost-COVID SyndromePost COVID-19 Condition, UnspecifiedPostinfectious InflammationPostinfectious Disorder

Interventions

DRUG

Nirmatrelvir/ritonavir

300/100 mg tablet twice daily (q12h) administered orally for 15 days

DRUG

Placebo/ritonavir

100mg tablet twice daily (q12h) administered orally for 15 days

Trial Locations (1)

SE171 77

Karolinska Institutet, Stockholm